A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Risk of subsequent primary oral cancer in a cohort of 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study
Tekijät: Sunguc Ceren, Hawkins Michael M., Winter David L., Dudley Isabelle M., Heymer Emma J., Teepen Jop C., Allodji Rodrigue S., Belle Fabien N., Bagnasco Francesca, Byrne Julianne, Bardi Edit, Ronckers Cecile M., Haddy Nadia, Gudmundsdottir Thorgerdur, Garwicz Stanislaw, Jankovic Momcilo, van der Pal Helena J. H., Mazic Maja Cesen, Schindera Christina, Grabow Desiree, Maule Milena M., Kaatsch Peter, Kaiser Melanie, Fresneau Brice, Michel Gisela, Skinner Roderick, Wiebe Thomas, Sacerdote Carlotta, Jakab Zsuzsanna, Gunnes Maria Winther, Terenziani Monica, Winther Jeanette F., Lähteenmäki Päivi M., Zaletel Lorna Zadravec, Kuehni Claudia E., Kremer Leontien C., Haupt Riccardo, de Vathaire Florent, Hjorth Lars, Reulen Raoul C.
Kustantaja: SPRINGERNATURE
Julkaisuvuosi: 2023
Journal: British Journal of Cancer
Tietokannassa oleva lehden nimi: BRITISH JOURNAL OF CANCER
Lehden akronyymi: BRIT J CANCER
Vuosikerta: 128
Numero: 1
Aloitussivu: 80
Lopetussivu: 90
Sivujen määrä: 11
ISSN: 0007-0920
eISSN: 1532-1827
DOI: https://doi.org/10.1038/s41416-022-02016-w
Verkko-osoite: https://doi.org/10.1038/s41416-022-02016-w
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/177324749
Background Survivors of childhood cancer are at risk of subsequent primary malignant neoplasms (SPNs), but the risk for rarer types of SPNs, such as oral cancer, is uncertain. Previous studies included few oral SPNs, hence large-scale cohorts are required to identify groups at risks.
Methods The PanCareSurFup cohort includes 69,460 5-year survivors of childhood cancer across Europe. Risks of oral SPNs were defined by standardised incidence ratios (SIRs), absolute excess risks and cumulative incidence.
Results One hundred and forty-five oral SPNs (64 salivary gland, 38 tongue, 20 pharynx, 2 lip, and 21 other) were ascertained among 143 survivors. Survivors were at 5-fold risk of an oral SPN (95% CI: 4.4-5.6). Survivors of leukaemia were at greatest risk (SIR = 19.2; 95% CI: 14.6-25.2) followed by bone sarcoma (SIR = 6.4, 95% CI: 3.7-11.0), Hodgkin lymphoma (SIR = 6.2, 95% CI: 3.9-9.9) and soft-tissue sarcoma (SIR = 5.0, 95% CI: 3.0-8.5). Survivors treated with radiotherapy were at 33-fold risk of salivary gland SPNs (95% CI: 25.3-44.5), particularly Hodgkin lymphoma (SIR = 66.2, 95% CI: 43.6-100.5) and leukaemia (SIR = 50.5, 95% CI: 36.1-70.7) survivors. Survivors treated with chemotherapy had a substantially increased risk of a tongue SPN (SIR = 15.9, 95% CI: 10.6-23.7).
Conclusions Previous radiotherapy increases the risk of salivary gland SPNs considerably, while chemotherapy increases the risk of tongue SPNs substantially. Awareness of these risks among both health-care professionals and survivors could play a crucial role in detecting oral SPNs early.
Ladattava julkaisu This is an electronic reprint of the original article. |  |
